Denmark
· Delayed Price · Currency is DKK Novozymes Statistics
Total Valuation
Novozymes has a market cap or net worth of DKK 188.05 billion. The enterprise value is 209.16 billion.
| Market Cap | 188.05B |
| Enterprise Value | 209.16B |
Important Dates
The next estimated earnings date is Wednesday, February 25, 2026.
| Earnings Date | Feb 25, 2026 |
| Ex-Dividend Date | Aug 21, 2025 |
Share Statistics
Novozymes has 465.60 million shares outstanding. The number of shares has decreased by -30.69% in one year.
| Current Share Class | 411.85M |
| Shares Outstanding | 465.60M |
| Shares Change (YoY) | -30.69% |
| Shares Change (QoQ) | -0.92% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 27.39% |
| Float | 346.32M |
Valuation Ratios
The trailing PE ratio is 28.28 and the forward PE ratio is 26.28. Novozymes's PEG ratio is 2.40.
| PE Ratio | 28.28 |
| Forward PE | 26.28 |
| PS Ratio | 6.08 |
| PB Ratio | 2.34 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 32.18 |
| P/OCF Ratio | 22.43 |
| PEG Ratio | 2.40 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.34, with an EV/FCF ratio of 35.79.
| EV / Earnings | 51.20 |
| EV / Sales | 6.76 |
| EV / EBITDA | 16.34 |
| EV / EBIT | 24.83 |
| EV / FCF | 35.79 |
Financial Position
The company has a current ratio of 1.61, with a Debt / Equity ratio of 0.29.
| Current Ratio | 1.61 |
| Quick Ratio | 0.98 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | 1.81 |
| Debt / FCF | 3.97 |
| Interest Coverage | 16.62 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 7.50% |
| Revenue Per Employee | 2.92M |
| Profits Per Employee | 386,063 |
| Employee Count | 10,582 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Novozymes has paid 1.13 billion in taxes.
| Income Tax | 1.13B |
| Effective Tax Rate | 21.69% |
Stock Price Statistics
The stock price has decreased by -2.82% in the last 52 weeks. The beta is 0.79, so Novozymes's price volatility has been lower than the market average.
| Beta (5Y) | 0.79 |
| 52-Week Price Change | -2.82% |
| 50-Day Moving Average | 400.65 |
| 200-Day Moving Average | 420.28 |
| Relative Strength Index (RSI) | 52.30 |
| Average Volume (20 Days) | 666,658 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Novozymes had revenue of DKK 30.94 billion and earned 4.09 billion in profits. Earnings per share was 14.28.
| Revenue | 30.94B |
| Gross Profit | 18.11B |
| Operating Income | 8.45B |
| Pretax Income | 5.22B |
| Net Income | 4.09B |
| EBITDA | 12.83B |
| EBIT | 8.45B |
| Earnings Per Share (EPS) | 14.28 |
Balance Sheet
The company has 2.10 billion in cash and 23.21 billion in debt, giving a net cash position of -21.11 billion or -45.34 per share.
| Cash & Cash Equivalents | 2.10B |
| Total Debt | 23.21B |
| Net Cash | -21.11B |
| Net Cash Per Share | -45.34 |
| Equity (Book Value) | 80.24B |
| Book Value Per Share | 171.68 |
| Working Capital | 5.56B |
Cash Flow
In the last 12 months, operating cash flow was 8.38 billion and capital expenditures -2.54 billion, giving a free cash flow of 5.84 billion.
| Operating Cash Flow | 8.38B |
| Capital Expenditures | -2.54B |
| Free Cash Flow | 5.84B |
| FCF Per Share | 12.55 |
Margins
Gross margin is 58.55%, with operating and profit margins of 27.32% and 13.20%.
| Gross Margin | 58.55% |
| Operating Margin | 27.32% |
| Pretax Margin | 16.86% |
| Profit Margin | 13.20% |
| EBITDA Margin | 41.48% |
| EBIT Margin | 27.32% |
| FCF Margin | 18.89% |
Dividends & Yields
This stock pays an annual dividend of 6.20, which amounts to a dividend yield of 1.53%.
| Dividend Per Share | 6.20 |
| Dividend Yield | 1.53% |
| Dividend Growth (YoY) | 61.25% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 73.62% |
| Buyback Yield | 30.69% |
| Shareholder Yield | 32.24% |
| Earnings Yield | 2.17% |
| FCF Yield | 3.11% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on November 28, 2011. It was a forward split with a ratio of 5.
| Last Split Date | Nov 28, 2011 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
Novozymes has an Altman Z-Score of 4.34 and a Piotroski F-Score of 4.
| Altman Z-Score | 4.34 |
| Piotroski F-Score | 4 |